Eris Lifesciences Launches Generic Semaglutide “SUNDAE” in India

Eris Lifesciences Ltd has launched its generic version of Semaglutide under the brand name “SUNDAE” in India. The product is designed for diabetes treatment and will initially cater to the domestic market. The launch date is set for March 21, 2026, as per the company’s filing with the BSE and NSE. This development is in accordance with Regulation 30 of the SEBI Listing Regulations.

The pricing for the SUNDAE multi-dose vial formats starts at INR 1,290 per month for the 2 mg/1.5 ml and 4 mg/3 ml variants. Additionally, a pen-device version is scheduled for release in April, with monthly prices set at INR 4,000, INR 4,200, and INR 4,500 for the strengths of 2mg/1.5ml, 4mg/3ml, and 8mg/3ml, respectively. These pricing strategies aim to make the therapy accessible to a significant portion of India’s diabetes patient population.

The scope of the launch includes the introduction of SUNDAE in multi-dose vial formats, with plans to enhance patient convenience through the pen-device version. Semaglutide is a GLP-1 receptor agonist, which has been recognized for its effectiveness in managing Type 2 diabetes and weight reduction. The product is expected to be distributed across India, leveraging Eris Lifesciences’ existing network of stockists and retail pharmacies.

The market context for this launch is characterized by a rapidly growing diabetic population in India. The introduction of SUNDAE aligns with the company’s strategy to expand its presence in the diabetes care segment. Eris Lifesciences has established a strong foothold in diabetology, engaging with specialists across the country. The addition of Semaglutide to its portfolio is part of its broader strategy to offer advanced diabetes therapies.

The timeline for the launch includes the initial availability of the multi-dose vial formats on March 21, 2026, followed by the pen-device version in April. The company has not indicated any international market plans for SUNDAE at this stage, focusing solely on the domestic market. The launch is part of Eris Lifesciences’ ongoing efforts to address the diabetes burden in India.

Eris Lifesciences Ltd is a prominent player in the Indian pharmaceutical industry, focusing on branded formulations. Established in 2007, the company has built a diversified presence across various specialties, including diabetes, cardiovascular, and neurology. Eris Lifesciences continues to invest in expanding its product offerings and enhancing its market presence in chronic care segments.